Table 2 Lipodystrophy type and location of patients enrolled in MEASuRE as of 31st October 2022
From: The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
Patients with GL, n (%) | Patients with PL, n (%) | |
|---|---|---|
United States* | 60 (89.6%) | 9 (56.3%) |
European Union | 7 (10.4) | 7 (43.7%) |
Total | 67 | 16 |